Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
May 8, 2020Outcomes presented at HRS 2020 SCIENCE demonstrate device benefits for patients at risk of sudden cardiac deathBoston Scientific (NYSE: BSX) today announced the final results from the UNTOUCHED study of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System presented at HRS 2020 SCIENCE, an...
May 8, 2020Trial meets primary safety and efficacy endpoints with low complication rates, 100% effective closure with next-generation stroke risk reduction technology for patients with non-valvular atrial fibrillationToday, Boston Scientific (NYSE: BSX) announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial...
-
Apr 29, 2020
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.543 billion during the first quarter of 2020. This represents growth of 2.0 percent on a reported basis, 3.2 percent on an...
-
Apr 2, 2020
The COVID-19 pandemic has brought unprecedented challenges upon the global community and the many healthcare providers who are caring for patients. During this time of concern and disruption,...
-
Feb 5, 2020
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.905 billion during the fourth quarter of 2019. This represents growth of 13.4 percent on a reported basis, 14.1 percent on an...
-
Jan 14, 2020
Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion during the fourth quarter of 2019. This represents...
Dec 13, 2019U.S. Food and Drug Administration Granted EXALT Model D Single-Use Duodenoscope Breakthrough Device Designation, Expediting Physicians' Access to a New, Sterile Device for Each PatientThe EXALT Model D Duodenoscope is the first and only FDA cleared single-use duodenoscope on the market.
-
Nov 12, 2019
Boston Scientific completed a public offering of €900.0 million aggregate principal amount of 0.625% Senior Notes due 2027.
-
Nov 6, 2019
Boston Scientific announced a public offering of €900.0 million aggregate principal amount of 0.625% Senior Notes due 2027.
-
Nov 5, 2019
Boston Scientific announced the commencement of a cash tender offer for up to $1.0 billion of outstanding senior notes.